Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide_2016

Date: October 19, 2016
Pages: 111
Price:
US$ 995.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P2E46DE9897EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide_2016
SUMMARY

The BRIC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY FINDINGS
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players' BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC pharmaceuticals market with five year forecasts
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
SYNOPSIS

Essential resource for top-line data and analysis covering the BRIC pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

REASONS TO BUY
  • What was the size of the BRIC pharmaceuticals market by value in 2015?
  • What will be the size of the BRIC pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the BRIC pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the BRIC pharmaceuticals market?
KEY HIGHLIGHTS
  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $155.5 billion in 2015. Russia was the fastest growing country with a CAGR of 21.6% over the 2011-15 period.
  • Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $97.9 billion in 2015. This was followed by India, Russia and Brazil with a value of $26.8, $16.9, and $13.9 billion, respectively.
  • China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $145.4 billion in 2020, followed by India, Russia, Brazil with expected values of $57.5, $24.9 and $19.2 billion, respectively.
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC Pharmaceuticals
Industry Outlook
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: BRIC pharmaceuticals industry, revenue($bn), 2011-20
Table 2: BRIC pharmaceuticals industry, revenue($bn), 2011-15
Table 3: BRIC pharmaceuticals industry, revenue($bn), 2015-20
Table 4: Brazil pharmaceuticals market value: $ billion, 2011-15
Table 5: Brazil pharmaceuticals market geography segmentation: $ billion, 2015
Table 6: Brazil pharmaceuticals market share: % share, by value, 2015
Table 7: Brazil pharmaceuticals market value forecast: $ billion, 2015-20
Table 8: Brazil size of population (million), 2011-15
Table 9: Brazil gdp (constant 2005 prices, $ billion), 2011-15
Table 10: Brazil gdp (current prices, $ billion), 2011-15
Table 11: Brazil inflation, 2011-15
Table 12: Brazil consumer price index (absolute), 2011-15
Table 13: Brazil exchange rate, 2011-15
Table 14: China pharmaceuticals market value: $ billion, 2011-15
Table 15: China pharmaceuticals market geography segmentation: $ billion, 2015
Table 16: China pharmaceuticals market share: % share, by value, 2015
Table 17: China pharmaceuticals market value forecast: $ billion, 2015-20
Table 18: China size of population (million), 2011-15
Table 19: China gdp (constant 2005 prices, $ billion), 2011-15
Table 20: China gdp (current prices, $ billion), 2011-15
Table 21: China inflation, 2011-15
Table 22: China consumer price index (absolute), 2011-15
Table 23: China exchange rate, 2011-15
Table 24: India pharmaceuticals market value: $ billion, 2011-15
Table 25: India pharmaceuticals market geography segmentation: $ billion, 2015
Table 26: India pharmaceuticals market share: % share, by value, 2015
Table 27: India pharmaceuticals market value forecast: $ billion, 2015-20
Table 28: India size of population (million), 2011-15
Table 29: India gdp (constant 2005 prices, $ billion), 2011-15
Table 30: India gdp (current prices, $ billion), 2011-15
Table 31: India inflation, 2011-15
Table 32: India consumer price index (absolute), 2011-15
Table 33: India exchange rate, 2011-15
Table 34: Russia pharmaceuticals market value: $ billion, 2011-15
Table 35: Russia pharmaceuticals market geography segmentation: $ billion, 2015
Table 36: Russia pharmaceuticals market share: % share, by value, 2015
Table 37: Russia pharmaceuticals market value forecast: $ billion, 2015-20
Table 38: Russia size of population (million), 2011-15
Table 39: Russia gdp (constant 2005 prices, $ billion), 2011-15
Table 40: Russia gdp (current prices, $ billion), 2011-15
Table 41: Russia inflation, 2011-15
Table 42: Russia consumer price index (absolute), 2011-15
Table 43: Russia exchange rate, 2011-15
Table 44: Aché Laboratórios Farmacêuticos S.A.: key facts
Table 45: EMS Sigma Pharma: key facts
Table 46: Sanofi SA: key facts
Table 47: Sanofi SA: key financials ($)
Table 48: Sanofi SA: key financials (€)
Table 49: Sanofi SA: key financial ratios
Table 50: Guangzhou Pharmaceutical Holdings Limited: key facts
Table 51: Shanghai Pharmaceuticals Holding Co Ltd: key facts
Table 52: Yangtze River Pharmaceutical Group: key facts
Table 53: Yunnan Baiyao Group Co., Ltd.: key facts
Table 54: Yunnan Baiyao Group Co., Ltd.: key financials ($)
Table 55: Yunnan Baiyao Group Co., Ltd.: key financials (CNY)
Table 56: Yunnan Baiyao Group Co., Ltd.: key financial ratios
Table 57: Aurobindo Pharma Limited: key facts
Table 58: Aurobindo Pharma Limited: key financials ($)
Table 59: Aurobindo Pharma Limited: key financials (Rs.)
Table 60: Aurobindo Pharma Limited: key financial ratios
Table 61: Lupin Limited: key facts
Table 62: Lupin Limited: key financials ($)
Table 63: Lupin Limited: key financials (Rs.)
Table 64: Lupin Limited: key financial ratios
Table 65: Dr. Reddy's Laboratories Limited: key facts
Table 66: Dr. Reddy's Laboratories Limited: key financials ($)
Table 67: Dr. Reddy's Laboratories Limited: key financials (Rs.)
Table 68: Dr. Reddy's Laboratories Limited: key financial ratios
Table 69: Sun Pharmaceutical Industries Ltd.: key facts
Table 70: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 71: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 72: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 73: Bayer AG: key facts
Table 74: Bayer AG: key financials ($)
Table 75: Bayer AG: key financials (€)
Table 76: Bayer AG: key financial ratios
Table 77: Novartis AG: key facts
Table 78: Novartis AG: key financials ($)
Table 79: Novartis AG: key financial ratios
Table 80: Pfizer Inc.: key facts
Table 81: Pfizer Inc.: key financials ($)
Table 82: Pfizer Inc.: key financial ratios
Table 83: F. Hoffmann-La Roche Ltd: key facts
Table 84: F. Hoffmann-La Roche Ltd: key financials ($)
Table 85: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 86: F. Hoffmann-La Roche Ltd: key financial ratios

LIST OF FIGURES

Figure 1: BRIC pharmaceuticals industry, revenue($bn), 2011-20
Figure 2: BRIC pharmaceuticals industry, revenue($bn), 2011-15
Figure 3: BRIC pharmaceuticals industry, revenue($bn), 2015-20
Figure 4: Brazil pharmaceuticals market value: $ billion, 2011-15
Figure 5: Brazil pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 6: Brazil pharmaceuticals market share: % share, by value, 2015
Figure 7: Brazil pharmaceuticals market value forecast: $ billion, 2015-20
Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2015
Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2015
Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2015
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2015
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2015
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2015
Figure 14: China pharmaceuticals market value: $ billion, 2011-15
Figure 15: China pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 16: China pharmaceuticals market share: % share, by value, 2015
Figure 17: China pharmaceuticals market value forecast: $ billion, 2015-20
Figure 18: Forces driving competition in the pharmaceuticals market in China, 2015
Figure 19: Drivers of buyer power in the pharmaceuticals market in China, 2015
Figure 20: Drivers of supplier power in the pharmaceuticals market in China, 2015
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2015
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2015
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in China, 2015
Figure 24: India pharmaceuticals market value: $ billion, 2011-15
Figure 25: India pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 26: India pharmaceuticals market share: % share, by value, 2015
Figure 27: India pharmaceuticals market value forecast: $ billion, 2015-20
Figure 28: Forces driving competition in the pharmaceuticals market in India, 2015
Figure 29: Drivers of buyer power in the pharmaceuticals market in India, 2015
Figure 30: Drivers of supplier power in the pharmaceuticals market in India, 2015
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2015
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2015
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in India, 2015
Figure 34: Russia pharmaceuticals market value: $ billion, 2011-15
Figure 35: Russia pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 36: Russia pharmaceuticals market share: % share, by value, 2015
Figure 37: Russia pharmaceuticals market value forecast: $ billion, 2015-20
Figure 38: Forces driving competition in the pharmaceuticals market in Russia, 2015
Figure 39: Drivers of buyer power in the pharmaceuticals market in Russia, 2015
Figure 40: Drivers of supplier power in the pharmaceuticals market in Russia, 2015
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2015
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2015
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2015
Figure 44: Sanofi SA: revenues and profitability
Figure 45: Sanofi SA: assets and liabilities
Figure 46: Yunnan Baiyao Group Co., Ltd.: revenues and profitability
Figure 47: Yunnan Baiyao Group Co., Ltd.: assets and liabilities
Figure 48: Aurobindo Pharma Limited: revenues and profitability
Figure 49: Aurobindo Pharma Limited: assets and liabilities
Figure 50: Lupin Limited: revenues and profitability
Figure 51: Lupin Limited: assets and liabilities
Figure 52: Dr. Reddy's Laboratories Limited: revenues and profitability
Figure 53: Dr. Reddy's Laboratories Limited: assets and liabilities
Figure 54: Sun Pharmaceutical Industries Ltd.: revenues and profitability
Figure 55: Sun Pharmaceutical Industries Ltd.: assets and liabilities
Figure 56: Bayer AG: revenues and profitability
Figure 57: Bayer AG: assets and liabilities
Figure 58: Novartis AG: revenues and profitability
Figure 59: Novartis AG: assets and liabilities
Figure 60: Pfizer Inc.: revenues and profitability
Figure 61: Pfizer Inc.: assets and liabilities
Figure 62: F. Hoffmann-La Roche Ltd: revenues and profitability
Figure 63: F. Hoffmann-La Roche Ltd: assets and liabilities
Skip to top


Ask Your Question

Pharmaceuticals BRIC (Brazil, Russia, India, China) Industry Guide_2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: